Are you Dr. Tumeh?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz
Suite 450
Los Angeles, CA 90095Phone+1 310-825-6911
Summary
- Dr. Paul Tumeh, MD is a board certified dermatologist in Los Angeles, California. He is currently licensed to practice medicine in California. He is affiliated with Ronald Reagan UCLA Medical Center and UCLA Medical Center-Santa Monica.
Education & Training
Los Angeles County-Harbor-UCLA Medical CenterResidency, Dermatology, 2008 - 2011
University of Pennsylvania Health SystemInternship, Internal Medicine, 2005 - 2006
Keck School of Medicine of the University of Southern CaliforniaClass of 2005
Certifications & Licensure
CA State Medical License 2008 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Publications & Presentations
PubMed
- 111 citationsImmunotherapy Resistance by Inflammation-Induced DedifferentiationArnav Mehta, Yeon Joo Kim, Lidia Robert, Jennifer Tsoi, Begoña Comin-Anduix
Cancer Discovery. 2018-08-01 - 122 citationsMAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during ImmunotherapyJulia Reinhardt, Jennifer Landsberg, Jonathan L. Schmid-Burgk, Bartomeu Bibiloni Ramis, Tobias Bald
Cancer Research. 2017-09-01 - 145 citationsPhase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.Jay M. Lee, Mi-Heon Lee, Edward B. Garon, Jonathan W. Goldman, Ramin Salehi-Rad
Clinical Cancer Research. 2017-08-15
Press Mentions
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial ResultsMarch 18th, 2019- Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory BoardNovember 9th, 2018
Professional Memberships
- Fellow
